Kyowa Hakko Kogyo Co., Ltd. licenses its in-house developed antibody KW-2871 targeting malignant melanoma to Life Science Pharma

07-Mar-2007

Kyowa Hakko Kogyo Co., Ltd. (KHK) agreed to license its in-house developed antibody KW-2871 to US pharmaceutical development company Life Science Pharmaceuticals (LSP). KHK grants to LSP an exclusive world-wide license to develop and market the compound. KW-2871 will be continued to be developed by the Ludwig Institute for Cancer Research (LICR) based in New York in collaboration with LSP. The compound entered Phase I/IIa clinical trials targeting a skin cancer, malignant melanoma, in 2002 in the US. After their completion, an additional study has been conducted to find the optimal dose.

Under this agreement, KHK will receive an upfront payment, milestone payments and royalties on sales of commercialized products from LSP.

KW-2871 is a chimeric monoclonal antibody specifically binding to the ganglioside antigen, GD3, expressed on the surface of malignant melanoma cells and exerts an anticancer effect by activating effector cells (natural killer cells, monocytes, etc.) which kill, mediated by antibodies, the target cells including cancer cells (antibody-dependent cellular cytotoxicity, ADCC), or destroying cell membranes with complement proteins (complement-dependent cytotoxicity).

Other news from the department science

These products might interest you

Hydrosart® Ultrafilter

Hydrosart® Ultrafilter by Sartorius

Efficient ultrafiltration for biotech and pharma

Maximum flow rates and minimum protein loss with Hydrosart® membranes

Ultra-filtration membranes
Hydrosart® Microfilter

Hydrosart® Microfilter by Sartorius

Hydrophilic microfilters for bioprocesses

Minimal protein adsorption and high flow rates

microfilters
Sartobind® Rapid A

Sartobind® Rapid A by Sartorius

Efficient chromatography with disposable membranes

Increase productivity and reduce costs with fast cycle times

membranes
Sartopore® Platinum

Sartopore® Platinum by Sartorius

Efficient filtration with minimal protein adsorption

Reduces rinsing volume by 95 % and offers 1 m² filtration area per 10"

filter membranes
Polyethersulfone Ultrafilter

Polyethersulfone Ultrafilter by Sartorius

Reliable filtration with PESU membranes

Perfect for biotechnology and pharmaceuticals, withstands sterilisation and high temperatures

membrane filters
Polyethersulfone Microfilter

Polyethersulfone Microfilter by Sartorius

Biotechnological filtration made easy

Highly stable 0.1 µm PESU membranes for maximum efficiency

microfilters
Loading...

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous